NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES)

Volume 7 Issue 2 Page 6-9, 2026

ONLINE ISSN:2992-5819 PRINT ISSN:2992-6149

Open Access

https://doi.org/10.59298/NIJSES/2026/72.69

Gestational Diabetes Mellitus: Maternal Hyperglycemia, Epigenetic Mechanisms, and Adverse Neonatal Outcomes

Abaho Areeba Fortunate

Department of Pharmacy Kampala International University Uganda
Email address: fortunate.abaho@studwc.kiu.ac.ug

ABSTRACT

Gestational diabetes mellitus (GDM) was a common condition that arises during pregnancy, characterized by maternal hyperglycemia. It had significant implications for both maternal and neonatal health. Recent research has focused on how maternal hyperglycemia induces epigenetic changes in the fetus, potentially leading to long-term adverse health outcomes in offspring. This review explored the relationship between maternal hyperglycemia, epigenetic mechanisms, and adverse neonatal outcomes in GDM, with a focus on the underlying molecular mechanisms and the potential long-term consequences for offspring. A comprehensive review of current literature on GDM pathophysiology, epigenetic alterations, and neonatal outcomes was conducted, including studies on DNA methylation, histone modifications, and non-coding RNA regulation. Maternal hyperglycemia during pregnancy induced epigenetic modifications in the fetus that affect fetal development, leading to an increased risk of metabolic disorders, such as obesity and diabetes, in later life. These epigenetic changes often involve genes related to insulin signaling, metabolism, and growth. Understanding the epigenetic mechanisms induced by GDM offers potential therapeutic avenues for mitigating the long-term adverse effects on offspring. Future research should focus on identifying specific epigenetic markers and exploring potential interventions.

Keywords: Gestational diabetes mellitus, Maternal hyperglycemia, Epigenetics, Neonatal outcomes, Fetal development.

INTRODUCTION

Gestational diabetes mellitus (GDM) is a pregnancy-related condition characterized by elevated blood glucose levels that typically develop during the second or third trimester [1, 2]. It is estimated to affect approximately 7% of pregnancies worldwide and is recognized as a major risk factor for maternal and neonatal complications. GDM has been linked to a range of adverse outcomes for both mothers and infants, including preterm birth, macrosomia (excessive birth weight), neonatal hypoglycemia, and an increased risk of developing type 2 diabetes and cardiovascular diseases later in life [3]. The pathophysiology of GDM involves insulin resistance, altered glucose metabolism, and hormonal changes during pregnancy. While these factors contribute to maternal hyperglycemia, the precise mechanisms by which hyperglycemia affects fetal development and health remain an area of active research.

Recent studies have suggested that epigenetic modifications induced by maternal hyperglycemia may play a crucial role in mediating the long-term consequences of GDM [4, 5]. Epigenetics refers to the changes in gene expression that do not involve alterations in the DNA sequence itself but rather involve modifications such as DNA methylation, histone modifications, and the regulation of non-coding RNAs. These epigenetic changes may affect fetal development and programming, potentially predisposing offspring to metabolic disorders, including obesity, insulin

resistance, and cardiovascular diseases, even in the absence of genetic predispositions. This review aims to explore the complex relationship between maternal hyperglycemia, epigenetic mechanisms, and adverse neonatal outcomes in GDM. It will examine the physiological mechanisms involved in GDM, the epigenetic changes induced by maternal hyperglycemia, and the long-term health outcomes observed in children born to mothers with GDM. The purpose of this study is to provide a comprehensive understanding of the impact of GDM on maternal and neonatal health and to highlight areas for future research that may lead to improved clinical management and prevention of long-term adverse outcomes.

Pathophysiology of Gestational Diabetes Mellitus

Gestational diabetes mellitus (GDM) is characterized by insulin resistance and inadequate insulin secretion, leading to maternal hyperglycemia [6]. During pregnancy, there are significant physiological changes that influence glucose metabolism, including hormonal changes mediated by placental hormones such as human placental lactogen (hPL) and cortisol [7]. These hormones promote insulin resistance to ensure that the fetus receives adequate glucose for growth. However, in some women, the pancreatic β-cells are unable to compensate for this insulin resistance, leading to the development of hyperglycemia.

Insulin resistance in GDM is often associated with obesity, age, and genetic predisposition [8]. Women with a family history of diabetes, particularly type 2 diabetes, are at higher risk of developing GDM [9]. Additionally, maternal obesity exacerbates insulin resistance, as excess adipose tissue releases inflammatory cytokines that impair insulin action. The combination of these factors results in elevated blood glucose levels, which in turn affects fetal development.

Maternal hyperglycemia can have a significant impact on fetal development, as excess glucose crosses the placenta, leading to fetal hyperglycemia and subsequent fetal insulin hypersecretion [10]. This can result in fetal macrosomia, a condition where the baby is born with an excessively high birth weight. Macrosomia increases the risk of delivery complications, including shoulder dystocia, and predisposes the infant to metabolic disorders later in life, such as obesity and type 2 diabetes.

Moreover, uncontrolled GDM can lead to other neonatal complications, including respiratory distress syndrome, hypoglycemia, and jaundice [11]. The long-term consequences of GDM on maternal health are also significant, as women who experience GDM are at increased risk of developing type 2 diabetes and cardiovascular disease later in life.

Maternal Hyperglycemia and Neonatal Outcomes

The effects of maternal hyperglycemia during pregnancy extend beyond the immediate neonatal period and can have lasting consequences for offspring's health. One of the most common neonatal complications associated with GDM is macrosomia, which occurs due to the excess glucose transferred to the fetus [12]. Fetal hyperglycemia leads to the overstimulation of insulin production, and insulin, being a growth-promoting hormone, contributes to excessive fetal growth.

Neonates born to mothers with GDM are also at increased risk for neonatal hypoglycemia [13, 14]. This occurs because the neonate, after birth, is no longer exposed to the high levels of glucose that were present in utero. However, the infant's insulin levels remain elevated due to the earlier fetal hyperglycemia, leading to a drop in blood glucose levels post-delivery. Hypoglycemia in the newborn can result in neurological complications if not promptly addressed.

In addition to these immediate effects, maternal hyperglycemia has been linked to an increased risk of long-term metabolic disorders in offspring. Children born to mothers with GDM are at higher risk for childhood obesity, insulin resistance, and type 2 diabetes later in life. This phenomenon, known as metabolic programming, suggests that early exposure to maternal hyperglycemia can alter fetal development in ways that predispose the child to metabolic diseases. The mechanisms underlying this programming are complex and involve not only genetic factors but also epigenetic modifications that influence gene expression.

Epigenetic Mechanisms in GDM

Epigenetic changes are alterations in gene expression that do not involve changes to the underlying DNA sequence but instead involve modifications to the DNA molecule or associated proteins that influence gene activity [15]. These changes are reversible and can be influenced by environmental factors, such as maternal diet, stress, and exposure to toxins. In the case of GDM, maternal hyperglycemia is a potent environmental factor that can induce epigenetic changes in the fetus.

DNA methylation, a well-studied epigenetic modification, involves the addition of a methyl group to the DNA molecule, typically at cytosine residues in CpG dinucleotides [16]. DNA methylation can repress gene expression and is a mechanism through which maternal hyperglycemia can influence fetal development. Studies have shown that maternal hyperglycemia is associated with altered DNA methylation patterns in genes involved in insulin signaling, glucose metabolism, and fetal growth.

Histone modifications, which involve the addition or removal of chemical groups to histone proteins around which DNA is wrapped, also play a key role in regulating gene expression [17]. These modifications can either promote

or inhibit gene transcription and are influenced by environmental factors, including maternal hyperglycemia. Additionally, non-coding RNAs, which do not code for proteins but regulate gene expression, have been implicated in the regulation of genes involved in metabolic processes. Changes in the expression of these non-coding RNAs in response to maternal hyperglycemia may further contribute to the long-term metabolic outcomes observed in offspring.

Impact of Epigenetic Changes on Fetal Development and Long-Term Health

The epigenetic changes induced by maternal hyperglycemia have profound implications for fetal development and the long-term health of offspring. During fetal development, the programming of key metabolic pathways occurs, and epigenetic modifications can influence the expression of genes involved in glucose metabolism, insulin sensitivity, and cell growth [18]. As a result, fetal exposure to maternal hyperglycemia can alter metabolic programming and increase the risk of metabolic diseases later in life.

One of the key targets of epigenetic modifications in GDM is the insulin signaling pathway. DNA methylation and histone modifications can alter the expression of genes involved in insulin receptor signaling, potentially leading to insulin resistance in the offspring. This increased susceptibility to insulin resistance can predispose children to obesity, type 2 diabetes, and other metabolic disorders as they grow older.

Additionally, epigenetic changes can affect the development of other organs, including the liver, muscle, and adipose tissue, all of which play crucial roles in maintaining metabolic homeostasis [19]. Altered gene expression in these tissues can contribute to the development of obesity and insulin resistance. The long-term health risks for offspring born to mothers with GDM are not limited to metabolic diseases; studies have also linked maternal hyperglycemia to an increased risk of cardiovascular diseases, including hypertension and atherosclerosis, in later life.

Future Research Directions and Clinical Implications

Given the growing evidence linking maternal hyperglycemia to epigenetic changes and long-term health risks for offspring [20, 21], there is a need for further research in this area. Future studies should focus on identifying specific epigenetic markers associated with GDM that can be used to predict adverse neonatal and long-term outcomes. These markers could potentially be used in clinical practice to identify high-risk pregnancies and guide personalized management strategies.

In addition to identifying epigenetic markers, research should also explore potential interventions to mitigate the effects of maternal hyperglycemia on fetal development. Lifestyle interventions, including dietary modifications and physical activity, have been shown to improve glycemic control in pregnant women with GDM and may also help reduce the impact of epigenetic changes. Furthermore, pharmacological interventions that target the epigenetic mechanisms involved in GDM may hold promise for preventing or reversing the long-term metabolic effects on offspring.

CONCLUSION

Gestational diabetes mellitus (GDM) is a major pregnancy complication that can have profound effects on both maternal and neonatal health. Maternal hyperglycemia during pregnancy leads to various adverse neonatal outcomes, including macrosomia, hypoglycemia, and long-term metabolic disorders. Emerging research has shown that maternal hyperglycemia induces epigenetic changes in the fetus, which can influence fetal development and increase the risk of obesity, insulin resistance, and cardiovascular diseases in offspring later in life. DNA methylation, histone modifications, and non-coding RNAs are critical epigenetic mechanisms that mediate the effects of maternal hyperglycemia on fetal programming. Future research should prioritize identifying specific epigenetic markers associated with GDM and developing interventions that target these changes, potentially reducing the long-term health risks for offspring born to mothers with GDM.

REFERENCES

1. Kunarathnam, V., Vadakekut, E.S., Mahdy, H.: Gestational Diabetes. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
2. Ugwu, O.P.-C., Erisa, K., Obeagu., E.I., Alum, E.U., Michael B, O., Subbarayan, S., Sankarapandiyan, V.: Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. INOSR ES. 12, 214–224 (2023). https://doi.org/10.59298/INOSRES/2023/2.17.1000
3. Liu, Y., Wang, M., Zhou, J.: Impact of Gestational Diabetes Mellitus on Neonatal Birth Outcomes. British Journal of Hospital Medicine. 85, 1–12 (2024). https://doi.org/10.12968/hmed.2024.0410
4. Vrachnis, N., Antonakopoulos, N., Iliodromiti, Z., Dafopoulos, K., Siristatidis, C., Pappa, K.I., Deligeoroglou, E., Vitoratos, N.: Impact of Maternal Diabetes on Epigenetic Modifications Leading to Diseases in the Offspring. Journal of Diabetes Research. 2012, 538474 (2012). https://doi.org/10.1155/2012/538474
5. Dłuski, D.F., Wolińska, E., Skrzypczak, M.: Epigenetic Changes in Gestational Diabetes Mellitus. International Journal of Molecular Sciences. 22, (2021). https://doi.org/10.3390/ijms22147649

6. Mittal, R., Prasad, K., Lemos, J.R.N., Arevalo, G., Hirani, K.: Unveiling Gestational Diabetes: An Overview of Pathophysiology and Management. International Journal of Molecular Sciences. 26, (2025). https://doi.org/10.3390/ijms26052320
7. Hassain, A.S.A.M., Asim: Metabolic Physiology in Pregnancy | DefinePK, https://define.pk/document.php?id=208723&type=article&jid=501
8. Feng, Y., Jiang, C.-D., Chang, A.-M., Shi, Y., Gao, J., Zhu, L., Zhang, Z.: Interactions among insulin resistance, inflammation factors, obesity-related gene polymorphisms, environmental risk factors, and diet in the development of gestational diabetes mellitus. The Journal of Maternal-Fetal & Neonatal Medicine. 32, 339–347 (2019). https://doi.org/10.1080/14767058.2018.1446207
9. Monod, C., Kotzaeridi, G., Linder, T., Eppel, D., Rosicky, I., Filippi, V., Tura, A., Hösli, I., Göbl, C.S.: Prevalence of gestational diabetes mellitus in women with a family history of type 2 diabetes in first- and second-degree relatives. Acta Diabetol. 60, 345–351 (2023). https://doi.org/10.1007/s00592-022-02011-w
10. Ning, J., Yang, H.: O-GlcNAcylation in Hyperglycemic Pregnancies: Impact on Placental Function. Front. Endocrinol. 12, (2021). https://doi.org/10.3389/fendo.2021.659733
11. Maternal and Neonatal Outcomes in Gestational Diabetes Mellitus: Review Article. The Egyptian Journal of Hospital Medicine. (2025). https://doi.org/10.21608/ejhm.2025.407386
12. KC, K., Shakya, S., Zhang, H.: Gestational Diabetes Mellitus and Macrosomia: A Literature Review. Ann Nutr Metab. 66, 14–20 (2015). https://doi.org/10.1159/000371628
13. Kole, M.B., Ayala, N.K., Clark, M.A., Has, P., Esposito, M., Werner, E.F.: Factors Associated With Hypoglycemia Among Neonates Born to Mothers With Gestational Diabetes Mellitus. Diabetes Care. 43, e194–e195 (2020). https://doi.org/10.2337/dc20-1261
14. Arimitsu, T., Kasuga, Y., Ikenoue, S., Saisho, Y., Hida, M., Yoshino, J., Itoh, H., Tanaka, M., Ochiai, D.: Risk factors of neonatal hypoglycemia in neonates born to mothers with gestational diabetes. Endocrine Journal. 70, 511–517 (2023). https://doi.org/10.1507/endocrj.EJ22-0521
15. Abdul, Q.A., Yu, B.P., Chung, H.Y., Jung, H.A., Choi, J.S.: Epigenetic modifications of gene expression by lifestyle and environment. Arch. Pharm. Res. 40, 1219–1237 (2017). https://doi.org/10.1007/s12272-017-0973-3
16. Dantas Machado, A.C., Zhou, T., Rao, S., Goel, P., Rastogi, C., Lazarovici, A., Bussemaker, H.J., Rohs, R.: Evolving insights on how cytosine methylation affects protein–DNA binding. Brief Funct Genomics. 14, 61–73 (2015). https://doi.org/10.1093/bfgp/elu040
17. Ramazi, S., Allahverdi, A., Zahiri, J.: Evaluation of post-translational modifications in histone proteins: A review on histone modification defects in developmental and neurological disorders. J Biosci. 45, 135 (2020). https://doi.org/10.1007/s12038-020-00099-2
18. Zhu, Z., Cao, F., Li, X.: Epigenetic Programming and Fetal Metabolic Programming. Front. Endocrinol. 10, (2019). https://doi.org/10.3389/fendo.2019.00764
19. Axsom, J.E., Schmidt, H.D., Matura, L.A., Libonati, J.R.: The Influence of Epigenetic Modifications on Metabolic Changes in White Adipose Tissue and Liver and Their Potential Impact in Exercise. Front. Physiol. 12, (2021). https://doi.org/10.3389/fphys.2021.686270
20. Amrom, D., Schwartz, S.S.: Maternal Metabolic Health, Lifestyle, and Environment – Understanding How Epigenetics Drives Future Offspring Health. Current Diabetes Reviews. 19, 50–73 (2023). https://doi.org/10.2174/1573399818666220422085016
21. Ornoy, A., Reece, E.A., Pavlinkova, G., Kappen, C., Miller, R.K.: Effect of maternal diabetes on the embryo, fetus, and children: Congenital anomalies, genetic and epigenetic changes and developmental outcomes. Birth Defects Research Part C: Embryo Today: Reviews. 105, 53–72 (2015). https://doi.org/10.1002/bdrc.21090

CITE AS: Abaho Areeba Fortunate (2026). Gestational Diabetes Mellitus: Maternal Hyperglycemia, Epigenetic Mechanisms, and Adverse Neonatal Outcomes. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES, 7(2):6-9.
https://doi.org/10.59298/NIJSES/2026/72.69